Valuation
- Market cap
- 5,756,000
- Revenue TTM
- $0
- Net income TTM
- $-6,940,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 29,948
- Avg volume
- 69,554
- Day's range
- $2.70 – $3.00
- Shares out
- 2,293,000
- Stochastic %K
- 45%
- Beta
- 1.72
- Analysts
- —
- Price target
- —
Company profile
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiar...
Show more
Psyence Biomedical Ltd., an integrated biopharmaceutical company, focuses on the development of botanical psilocybin-based psychedelic medicines. Its lead product candidate is NPX-5, a botanical drug candidate that is in Phase IIb clinical study for the treatment of adjustment disorder in patients with cancer in a palliative care setting. The company is based in Toronto, Canada. Psyence Biomedical Ltd. is a subsidiary of Psyence Group Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 416-477-1708
- Website
- https://psyencebiomed.com
- Address
- 121 Richmond Street West, Penthouse Suite 1300, Toronto, Canada
Latest news
No headlines yet.